Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer

E Richardsen, S Andersen, S Al-Saad, M Rakaee, Y Nordby, M I Pedersen, N Ness, L M Ingebriktsen, A Fassina, K A Taskén, I G Mills, T Donnem, R M Bremnes, L T Busund

Research output: Contribution to journalArticle

5 Citations (Scopus)
118 Downloads (Pure)

Abstract

Prostate cancer (PC) is a highly heterogenous disease and one of the leading causes of mortality in developed countries. Recently, studies have shown that expression of immune checkpoint proteins are directly or indirectly repressed by microRNAs (miRs) in many types of cancers. The great advantages of using miRs based therapy is the capacity of these short transcripts to target multiple molecules for the same- or different pathways with synergistic immune inhibition effects. miR-424 has previously been described as a biomarker of poor prognosis in different types of cancers. miR-424 is also found to target both the CTLA-4/CD80- and PD-1/PD-L1 axis. In the present study, the clinical significance of miR-424-3p expression in PC tissue was evaluated. Naïve radical prostatectomy specimens from 535 patients was used for tissue microarray construction. In situ hybridization was used to evaluate the expression of miR-424-3p and immunohistochemistry was used for CTLA-4 protein detection. In univariate- and multivariate analyses, low expression of miR-424-3p was significant associated with clinical failure-free survival, (p = 0.004) and p = 0.018 (HR:0.44, CI95% 0.22-0.87). Low expression of miR-424-3p also associated strongly with aggressive phenotype of PC. This highlight the importance of miR-424-3p as potential target for therapeutic treatment in prostate cancer.

Original languageEnglish
Pages (from-to)10662
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 23 Jul 2019

Fingerprint Dive into the research topics of 'Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer'. Together they form a unique fingerprint.

  • Cite this

    Richardsen, E., Andersen, S., Al-Saad, S., Rakaee, M., Nordby, Y., Pedersen, M. I., Ness, N., Ingebriktsen, L. M., Fassina, A., Taskén, K. A., Mills, I. G., Donnem, T., Bremnes, R. M., & Busund, L. T. (2019). Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. Scientific Reports, 9(1), 10662. https://doi.org/10.1038/s41598-019-47234-0